Last reviewed · How we verify
R-BL-M-04
R-BL-M-04 is a small molecule Small molecule drug developed by Elena N.Parovichnikova. It is currently in Phase 3 development for unknown.
R-BL-M-04 is a small molecule drug that targets the molecular target.
R-BL-M-04 is a small molecule intervention. It is being studied in a clinical trial for the treatment of High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | R-BL-M-04 |
|---|---|
| Sponsor | Elena N.Parovichnikova |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | unknown |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of R-BL-M-04 is not well understood, but it is believed to work by interacting with the molecular target, leading to a specific therapeutic effect.
Approved indications
- unknown
Common side effects
- unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-BL-M-04 CI brief — competitive landscape report
- R-BL-M-04 updates RSS · CI watch RSS
- Elena N.Parovichnikova portfolio CI
Frequently asked questions about R-BL-M-04
What is R-BL-M-04?
How does R-BL-M-04 work?
What is R-BL-M-04 used for?
Who makes R-BL-M-04?
What drug class is R-BL-M-04 in?
What development phase is R-BL-M-04 in?
What are the side effects of R-BL-M-04?
What does R-BL-M-04 target?
Related
- Drug class: All small molecule drugs
- Target: All drugs targeting unknown
- Manufacturer: Elena N.Parovichnikova — full pipeline
- Therapeutic area: All drugs in unknown
- Indication: Drugs for unknown
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing